Regeneron Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Regeneron Pharmaceuticals (Tarrytown, NY): 9 reconciled FDA prescription therapies, $5.74B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Tarrytown, NY |
| Reconciled FDA Portfolio Therapies | 9 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $5.74B |
| 2024 Medicare Part D Spend | $2.94B |
| 2024 Medicaid Spend | $2.81B |
| California HCAI SB 17 Filings | 15 WAC filings (max 18.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.